Background. Dexmedetomidine has been proposed as a perineural local anaesthetic (LA) adjunct to prolong peripheral nerve block duration; however, results from our previous meta-analysis in the setting of brachial plexus block (BPB) did not support its use. Many additional randomized trials have since been published. We thus conducted an updated metaanalysis. Methods. Randomized trials investigating the addition of dexmedetomidine to LA compared with LA alone (Control) in BPB for upper extremity surgery were sought. Sensory and motor block duration, onset times, duration of analgesia, analgesic consumption, pain severity, patient satisfaction, and dexmedetomidine-related side-effects were analysed using randomeffects modeling. We used ratio-of-means (lower confidence interval [point estimate]) for continuous outcomes. Results. We identified 32 trials (2007 patients), and found that dexmedetomidine prolonged sensory block (at least 57%, P < 0.0001), motor block (at least 58%, P < 0.0001), and analgesia (at least 63%, P < 0.0001) duration. Dexmedetomidine expedited onset for both sensory (at least 40%, P < 0.0001) and motor (at least 39%, P < 0.0001) blocks. Dexmedetomidine also reduced postoperative oral morphine consumption by 10.2mg [-15.3, -5.2] (P < 0.0001), improved pain control, and enhanced satisfaction. In contrast, dexmedetomidine increased odds of bradycardia (3.3 [0.8, 13.5](P ¼ 0.0002)), and hypotension (5.4 [2.7, 11.0] (P < 0.0001)). A 50-60mg dexmedetomidine dose maximized sensory block duration while minimizing haemodynamic side-effects. No patients experienced any neurologic sequelae. Evidence quality for sensory block was high according to the GRADE system. Conclusions. New evidence now indicates that perineural dexmedetomidine improves BPB onset, quality, and analgesia. However, these benefits should be weighed against increased risks of motor block prolongation and transient bradycardia and hypotension.
Anaesthetists have sought strategies to extend the benefits of single-shot peripheral nerve blocks beyond the duration of commonly available local anaesthetics (LA). 1 Perineural adjuncts are one technically simple strategy that can be used for this purpose. 2 Dexmedetomidine, an alpha-2 agonist, 3 has been proposed as a safe 4 and effective 56 adjunct capable of extending the duration of single-shot block. Hyperpolarization-activated cation currents normally bring neurons back to the resting potential and normal functional activity during the refractory phase in an action potential. By blocking these currents, dexmedetomidine can accentuate inhibition of neuronal conduction and produce analgesia. 6 However, despite early promising evidence from animal 56 and human 7 studies that have signaled efficacy, our quantitative systematic review of dexmedetomidine as an adjunct to brachial plexus block (BPB), published in 2013, 8 was unable to demonstrate any clinically important benefits. Some of the trials 7 9-11 were marked by substantial clinical and statistical heterogeneities that may have undermined a precise estimation of the dexmedetomidine treatment effect. Many additional trials of dexmedetomidine as a BPB adjunct have been since published, thus prompting a re-examination specifically to assess the role of dexmedetomidine in prolonging sensory block duration.
Methods
We followed PRISMA statement guidelines 12 in the preparation of this manuscript. Randomized trials examining the effect of dexmedetomidine on the duration of sensory block after singleshot BPB were evaluated using a predefined protocol, but this was not previously published.
Literature search
Two of the authors (LV and FWA) independently sought and retrieved relevant studies from electronic databases including the US National Library of Medicine database, MEDLINE; the Excerpta Medica database, EMBASE; the Cochrane Databases of systematic reviews; the Cochrane central register of controlled clinical trials; Cumulative Index of Nursing and Allied Health Literature (CINAHL); Scopus; Web of Science; MEDLINE InProcess; and other non-indexed citations. The medical subject headings (MeSH), text words, and controlled vocabulary terms relating to Dexmedetomidine and Medetomidine were sought. Results were combined using the Boolean operator "AND" with the search terms analgesia, anaesthesia, adjunct, adjuvant, anaesthetics local, nerve block, perineural, regional anaesthesia and terms designating upper extremity such as arm, brachial plexus, forearm, elbow, hand, humerus, radius, shoulder, and wrist. Additional non-indexed articles were retrieved using Google Scholar; and the bibliographies of retrieved trials were hand-searched for additional relevant studies. Our search was limited to randomized trials published in the English language. Only trials including adults (age > 18 yr) published in fullmanuscript form between January 1985 and February 2016 were considered. Abstracts were excluded.
Inclusion criteria
We included randomized trials with parallel group design examining the effects of adding perineural dexmedetomidine as an adjunct to LA (Dex group), compared with LA alone (Control group) on BPB characteristics, postoperative analgesia and dexmedetomidine-related side-effects, in patients undergoing upper extremity surgery with BPB. Specifically, interscalene (ISB), supraclavicular (SCB), infraclavicular (ICB) and axillary (AXB) level blocks of the brachial plexus performed for either anaesthesia or postoperative analgesia were considered. Randomized and quasirandomized, and single-and double-blinded trials were included. Randomized trials without a control group were excluded. We also excluded trials if non-perineural routes of dexmedetomidine administration were used (e.g. intra-articular injection); 13 if surgeries involved anatomical areas other than the upper extremity (e.g. abdominal); 14 and if blocks other than BPB were performed. 15 Studies of i.v. regional anaesthesia 16 17 and distal peripheral nerve blocks (e.g. medial, radial or ulnar blocks) 18 19 were also excluded.
Trial selection and methodological assessment
The two authors (LV and FWA) independently evaluated the identified abstracts. Inclusion of qualifying studies in the review was taken by consensus between the two authors. Disagreements were resolved by re-evaluating the full manuscript of the source studies and consulting with the third author (RB). Trials that failed to meet the inclusion criteria were excluded. The quality of the reviewed trials was independently assessed using the Cochrane Collaboration Risk of Bias tool 20 by two of the authors (LV and FWA). The tool evaluates trials for biases, among which are selection (randomization and allocation), performance and detection (blinding), attrition, reporting, and other forms of bias. A score was assigned to each trial by consensus; if an agreement could not be reached, the third author (RB) was consulted. Considering the limited number of studies and that our earlier meta-analysis failed to demonstrate the effects of dexmedetomidine on nerve blocks, we decided not to exclude studies based on the quality scores, but rather to take an inclusive approach towards studies with a view towards answering the question of interest. However, trials were excluded if they had fewer than 10 subjects per group, to reduce the possibility of chance in estimating a treatment effect.
(e.g. dexamethasone 21 , fentanyl 22 ) were extracted but excluded from the final analysis.
Outcomes assessed
We designated sensory block duration (min), defined as time from completion of LA injection to full recovery from sensory block, as a primary outcome. Secondary outcomes included block characteristics, namely motor block duration (min), and sensory and motor block onset times (min), defined as time from completion of LA injection to achieving full sensory and motor block, respectively. We also evaluated analgesic outcomes comprising duration of analgesia (min), defined as time to first analgesic request, or as defined by authors; cumulative analgesic consumption during the first 24 h postoperatively, expressed as oral morphine equivalents (mg); 23 rest and dynamic postoperative pain severity (visual analogue scale, VAS; 0 ¼ no pain, 10 ¼ worst pain imaginable) at 12 and 24 h postoperatively; patient satisfaction with postoperative pain relief, (VAS; 0 ¼ least satisfied, 10 ¼ most satisfied); and length of hospital stay. Also included were frequency of dexmedetomidine-related adverse effects (bradycardia, hypotension, excessive sedation, hypoxemia) 24 and postoperative nausea and vomiting (PONV), as defined by authors, and block-related complications.
For the purpose of this review, trials reporting the range or interquartile range (IQR) were included using an estimate of the standard deviation (SD), using the formulas: SD¼ Range/4 and SD¼ IQR/1.35, respectively, as described by the Cochrane Handbook for Systematic Reviews. 25 Data reported as 95% confidence intervals (CI) were similarly used to estimate the range, and were converted to SD. The median was used to estimate the mean if its value was not provided. 26 Postoperative pain severity reported as numerical rating scale scores or verbal rating scale scores was converted to VAS scores. 27 
Predefined sources of heterogeneity
To explore potential causes of heterogeneity in our results, we pre-identified the clinical characteristics of individual trials and known confounders that may lead to variations in our primary outcome results (sensory block duration). The variables of interest included i) level of BPB, ii) LA dose, iii) dexmedetomidine dose, iv) epinephrine dose, v) block localization technique, and vi) nature of surgical anaesthetic used (general anaesthesia vs nerve block). Based on the clinical assumption that different levels of BPB will lead to different block characteristics and analgesic effects, we planned to separately analyse outcomes according to the type of BPB performed (interscalene, supraclavicular, infraclavicular, and axillary). The degree to which the remaining factors can predict the duration of sensory block (primary outcome) was evaluated using meta-regression analysis.
Statistical analysis
We used data presented in tables as the primary source for extraction; when data were not presented in tables, we contacted authors for additional information. Graphical data not otherwise available in the text or from the authors were estimated from figures. As a final resort, when SD values were not reported for an outcome (e.g. postoperative pain), 9 28 these values were imputed. 29 30 Dichotomous data relating to side-effects were converted to incidence (n/N) during a given time interval; and the single highest incidence was used to capture the proportion of patients who experienced a certain side-effect at least once. Data from trials with more than two intervention groups receiving different doses of perineural dexmedetomidine were combined into a single group as per the Cochrane Handbook. 30 We analysed results on an intention-to-treat basis by analysing the data available from all participants in each study group, regardless of compliance or attrition, to estimate the influence on treatment effect. 31 Continuous data describing patient satisfaction were converted to odds ratios (OR) to facilitate quantitative analysis. 32 33 were used to combine the data where possible. As a variety of BPB and upper extremity procedures were examined, we selected the DerSimonian random effect modeling to pool the results. 34 The strength of evidence pooled from the trials reviewed was assessed using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) guidelines. 35 In contrast to other assessment tools that evaluate quality across outcomes within a given trial, the GRADE tool evaluates quality across trials for each outcome. Based on key elements including study quality, consistency, directness, precision, and publication bias, the GRADE tool classifies the strength of synthesized evidence into four categories: i) high quality: further research is very unlikely to change the confidence in the estimate of effect; ii) moderate quality: further research is likely to have an important impact on the confidence in the estimate of effect and may change the estimate; iii) low quality: further research is very likely to have an important impact on the confidence in the estimate of effect and is likely to change the estimate; and iv) very low quality: we are very uncertain about the estimate. For consistency in specific, we resorted to examining the similarity of point estimates, and the extent of overlap of confidence intervals, in addition to testing heterogeneity using the I 2 statistic.
Meta-analysis
All time-to-event outcomes, including block characteristics (sensory and motor block onset and duration), and the duration of analgesia, the ratio of means, standard error, and 95% CIs were calculated for all continuous outcomes that examined change from baseline. 36 37 For the remaining outcomes, the OR and 95% CIs were reported for dichotomous outcomes, while the weighted mean difference and 95% CI were reported for continuous outcomes. Differences were considered statistically significant when the P-value was < 0.05 and the 95% CI did not include 1 for OR and 0 for the standardized mean difference. Heterogeneity of the pooled results was assessed using the I 2 statistic. 38 When heterogeneity was significant (I 2 > 50%), we planned to explore the sources of heterogeneity of the primary outcome data (i.e. sensory block duration), by examining the association with pre-specified confounders. The risk of publication bias was evaluated by checking for asymmetry of the funnel plots, as described in the Egger regression test. 39 
Results
Our database search strategy retrieved 137 potentially relevant records published between 2010 and 2016, including 15 from non-indexed citations. Of these, 102 records were excluded after initial screening; and another record was excluded for duplicated work. 40 None of the remaining records involved less than 10 subjects per group. A total of 34 full-text randomized trials 7 9-11 21 22 28 41-67 were included in the final analysis. Figure 1 represents the preferred reporting items for systematic reviews and meta-analyses (PRISMA) 12 flow diagram, and summarizes the reasons for exclusion of records. 65 and not defined in one trial. 44 With the exception of one trial that used mepivacaine, 66 all trials used long-acting LAs (ropivacaine, bupivacaine, or levobupivacaine) alone or in conjunction with short acting LAs; and three trials used epinephrine in all study arms. 60 64 65 Perineural dexmedetomidine was used in either weight-based doses (0.75 to 1.0 mg/kg) or flat doses (10 to 150 mg). A combination of perineural bolus and infusion of dexmedetomidine was used in one study; in this case, we excluded all outcomes influenced by the infusion. 60 Eight trials examined adjuncts other than perineural dexmedetomidine; 8 21 43 51 59 these study arms were excluded from the analysis as they did not meet the inclusion criteria. Two trials included two 
Trial characteristics
perineural dexmedetomidine arms 54 with different doses, which were combined into a single group for the purpose of this analysis. All trials reported block characteristics, analgesic outcomes, and dexmedetomidine-related complications.
Risk of bias assessment
Some of the studies reviewed lacked sufficient details to permit full evaluation of the risk of bias; in such cases, we were conservative in our risk of bias evaluation by tending to classify trials as having an "unclear risk of bias" when the complete details that allow the exclusion of selection, performance and detection biases were not reported. Furthermore, trials that used generalizations such as "similar side-effects between study groups", or presented haemodynamic outcomes data in a graphical format that precluded determining the actual risk of side-effects, were considered to be at a high risk for selective reporting. The reviewers' consensus assessment of the risk is detailed in Table 2 . Considering our conservative approach, and the fact that the main outcomes of interest, namely block characteristics, were less likely to be affected by the aforementioned biases, we considered the methodological quality for the majority of the 34 trials included to be acceptable, and rated the overall risk of bias across the studies as moderate. Most of trials had low risk for selection bias, attrition bias, and other biases; moreover, the majority of trials were assigned unclear risk of selection and performance bias, because authors did not provide sufficient details regarding blinding and concealment of sequence allocation. Bias as a result of selective reporting was classified as high in most of the trials, because of the aforementioned conservative approach in assessing the reporting of the dexmedetomidine-related haemodynamic side-effects. None of the trials were quasi-randomized.
Sensory block duration
Data describing the primary outcome, sensory block duration (time to full recovery from sensory block), were available from all trials (910 patients in Dex group) except two, 8 60 and are presented in Figure 2 . The primary outcome results were characterized by significant heterogeneity for all four subgroups. Performing metaregression analysis using the a priori pre-specified confounders, namely the LA dose, dexmedetomidine dose, epinephrine dose, block localization technique, and nature of surgical anaesthetic, yielded omnibus P-values of 0.047, 0.948, 0.37, 0.09, and 0.215, respectively, suggesting that the total LA dose is a predictor of sensory block prolongation.
Based on the fact that 15 trials were contributed by nonindexed citations, we elected to perform an additional subgroup analysis to assess the influence of potential selection bias introduced by including non-indexed trials. This analysis indicated that dexmedetomidine prolonged sensory block duration by at least 46% [60] , (P < 0.0001, I
2 ¼ 99%) and 58% [70] , (P < 0.0001,
for the indexed and non-indexed trials, respectively.
There was no difference between the two subgroups (P ¼ 0.3), and heterogeneity remained high. Finally, the funnel plot did not suggest significant publication bias (P ¼ 0.08) for our primary outcome.
When the strength of the synthesized evidence was evaluated using the GRADE guidelines, there was high evidence that mixing dexmedetomidine with long-acting LA used in a BPB, regardless of the level, prolongs the duration of sensory block duration compared with LA alone, in patients undergoing upper extremity surgery (Table 3) . The overall quality assessment was downgraded by quality limitations; but was also upgraded by the large treatment effect and presence of a dose response.
Block characteristics
The effect of perineural dexmedetomidine on motor block duration was evaluated in 31 trials. 7 (Fig. 3) . The overall treatment effect for all levels of BPB suggested that dexmedetomidine prolongs motor block duration by at least 58% [68%], (P < 0.0001, I 2 ¼ 100%), or from 6.9 h to 10.1 h.
The level of evidence for this finding was rated as high. (Table 3) The overall quality assessment was downgraded by quality limitations; but was also upgraded by the large treatment effect. The effect of perineural dexmedetomidine as a LA adjunct o n the sensory block onset was evaluated in 31 trials. 7 Table 3 ).
The overall treatment effect for all levels of BPB suggested that dexmedetomidine shortened sensory block onset time by at least 40% [28%], (P < 0.0001, I 2 ¼ 98%), or from 20.0 min to 10.8 min. The level of evidence for this finding was rated as moderate. (Table 3 , Supplementary Fig. S1 ) The overall quality assessment was downgraded by quality and consistency limitations; but was also upgraded by the large treatment effect. The effect of perineural dexmedetomidine on motor block onset was assessed in 27 trials. 65 67 Dexmedetomidine hastened motor block onset by at least 35% [26%], (P < 0.0001, I 2 ¼ 96%) for SCB; 40% [31%], (P < 0.0001, I 2 ¼ 0%)
for ICB; and 17% [15%], (P < 0.0001, I 2 ¼ 26%) for AXB (Table 3) .
Though both trials 52 55 examining the effect of dexmedetomidine on motor block onset time in ISB showed faster motor block onset, the pooled results for this specific brachial plexus level was not significant. The overall treatment effect for all levels of BPB suggested that dexmedetomidine shortened motor block onset time by at least 39% [27%], (P < 0.00001, I 2 ¼ 99%), or from 21.2 min to 13.4 min. The level of evidence for this finding was rated as moderate. (Table 3 , Supplementary Fig. S2 ) The overall quality assessment was downgraded by quality and consistency limitations; but was also upgraded by the large treatment effect.
Analgesic outcomes
The effect of perineural dexmedetomidine on duration of postoperative analgesia was evaluated in 26 trials. Table 3) . The overall treatment effect for all levels of BPB suggested that dexmedetomidine prolonged the duration of analgesia by at least 63% [72%], (P < 0.0001, I 2 ¼ 100%), or from 7.5 h to 11.9 h. The level of evidence for this finding was rated as moderate. (Table 3 , Supplementary Fig. S3 ) The overall quality assessment was downgraded by quality, consistency, and directness limitations; but was also upgraded by the large treatment effect and doseresponse.
Cumulative 24-h postoperative analgesic consumption was reported in eight trials belonging to the ISB 43 of oral morphine equivalents. The level of evidence for this finding was rated as low. (Table 3 ) The overall quality assessment was downgraded by quality and sparse data limitations. The effect of perineural dexmedetomidine on posto perative rest pain scores at 24 h was reported in seven trials. and AXB subgroups, respectively but there were no differences in the ISB and ICB subgroups. The level of evidence for this finding was rated as low. (Table 3 ) The overall quality assessment was downgraded by quality and sparse data limitations. Rest pain at 12 h and length of hospital stay time were inconsistently assessed in the reviewed trials; while dynamic pain was reported in one trial only, 55 precluding any conclusions regarding these outcomes. Patient satisfaction with the pain management received and/or willingness to receive the same management in the future was assessed in six trials. 8 (Table 3) The overall quality assessment was downgraded by quality, consistency and sparse data limitations.
Dexmedetomidine-related adverse effects
The definitions of dexmedetomidine-related adverse effects in the reviewed trials were diverse; therefore, we reported these outcomes as 'standardized units'. Dexmedetomidine increased the odds of bradycardia by an OR of 3.3 [0.8, 13.5], (P ¼ 0.0002, I 2 ¼ 70%); it also increased the odds of hypotension by an OR of 5.4 [2.7, 11 .0], (P < 0.0001, I 2 ¼ 0%). The level of evidence for these findings was rated as moderate. (Table 3 ) The overall quality assessment was downgraded by quality and consistency limitations. Notably, these side-effects were transient, reversible, did not require any intervention, and did not cause any long-term consequence in any of the patients. Our additional subgroup analysis suggested that a dose of 50-60 mg maximizes sensory block duration (by at least 52% [61%], P < 0.0001), while minimizing the haemodynamic side-effects to none [i.e. by an OR of 1.7 
Discussion
This is the first study to provide a high level of evidence from clinical trials supporting the efficacy of perineural dexmedetomidine as peripheral nerve block adjunct. Our updated review demonstrates that using perineural dexmedetomidine as a BPB adjunct is associated with important facilitatory effects regardless of the BPB level, specifically prolonged sensory and motor block durations, and faster sensory and motor block onset. The analgesic benefits of using dexmedetomidine include prolonged duration of analgesia, reduced cumulative 24 h postoperative analgesic consumption, improved pain control and enhanced satisfaction with pain relief. However, perineural dexmedetomidine was also associated with increased risk of transient hypotension, bradycardia, and postoperative sedation. The levels of evidence relating to sensory block duration and duration of analgesia were high and moderate, respectively. The observed differences in the magnitude of dexmedetomidine effects on the various BPB levels may be attributed to intrinsic differences in the systemic uptake 69 and neuraxial spread 70 between these levels. This updated systematic review and meta-analysis overcomes the limitations of our earlier meta-analysis 8 of a small number of trials that had suggested lack of efficacy of dexmedetomidine in prolonging sensory block duration or expediting block onset. However, the present results are similarly characterized by high heterogeneity, and while LA dose-response account for some of this heterogeneity, our findings should still be interpreted with caution. The benefits of dexmedetomidine should be carefully weighed against prolonged motor block duration and the increased risks of sedation, bradycardia and hypotension. Practically, while extended motor block duration may be desirable in certain populations, using dexmedetomidine in lower extremity blocks may delay recovery after ambulatory surgery and increase the risk of falls. 71 72 Additionally, sedation may interfere with fast-tracking, recovery room bypass, or other pathways aimed to expedite discharge. The potential for haemodynamic side-effects may limit the administration of blocks inclusive of dexmedetomidine to monitored settings, where bradycardia and hypotension can be readily identified and treated. Furthermore, these side-effects may preclude use in higher risk patients and in procedures inherently associated with changes in heart rate and bp, such as surgery in the sitting position.
73
This meta-analysis has positive safety implications. While our previous meta-analysis 8 could not draw conclusions about the safety of the clinical use of dexmedetomidine, the present review incorporates data from 1026 patients who received perineural dexmedetomidine for the BPB, and none developed any neurotoxicity symptoms, or any other neurologic sequalae. In fact, there is further evidence from in vitro and animal studies suggesting that the perineural application of dexmedetomidine may be neuroprotective against the LA-induced inflammatory response. 5 74 75 While this has also been shown for clonidine, 76 the latter may carry a risk of neurotoxicity when combined with local anaesthetics. 4 Nonetheless, recent evidence suggesting that systemic dexmedetomidine may be as effective as perineural dexmedetomidine in prolonging the duration of analgesia after BPB, is a promising new area of research, 8 though the underlying mechanisms and the comparative risk of haemodynamic side-effects have yet to be explored.
Limitations
Our review has several limitations. First, clinical heterogeneity characterized the data reviewed as it originated from different surgical, anaesthetic, and analgesic settings. While we stratified studies according to the level of BPB, considerable variability may persist within each subgroup. For example, postoperative pain after shoulder rotator cuff repair is likely more severe than simple shoulder arthroscopy; but lack of sufficient data precluded any further stratification by surgical procedure. Second, definitions of some outcomes of interest, such as postoperative analgesia duration, hypoxaemia, and excessive sedation varied between trials, which may have contributed to the observed heterogeneity. Third, the trials reviewed were small, with sample sizes of 10-50 patients/group, which increases the chances of type I error and publication bias. Fourth, only two trials originated from North America 64 and Europe, 55 which may represent another source of publication bias. 7778 Fifth, while a variety of doses of dexmedetomidine were used, we could not detect a dose-response, although evidence suggests that dexmedetomidine produces a dose-dependent prolongation in sensory block duration. 19 This may be as a result of the clinical heterogeneity of nerve block techniques and LA doses used. We also did not seek abstracts from meeting and trial results from clinical trial registries, and we restricted our search to trials published in the English language. Lastly, it is noteworthy that the methodological shortcomings of studies and inconsistencies in the definition and assessment of outcomes were main reasons why the strength of evidence was down-graded for some outcomes. Despite these inconsistencies, the methods of assessing outcomes indicative of dexmedetomidine effectiveness (i.e. durations of sensory block, motor block, and postoperative analgesia), were marked by good internal and external validity. Furthermore, factors such as the strength of the treatment effect, presence of a dose-response, and successful identification of confounders served to offset these limitations for some outcomes.
In contrast, our review has several points of strength. The literature review we conducted was exhaustive and included all relevant databases. Our inclusion criteria were limited to randomized trials. The primary outcome results maintained their robustness despite our attempt to explore statistical heterogeneity. These factors underscore the validity of our findings.
Conclusion
Our study provides strong evidence that using perineural dexmedetomidine improves BPB onset, quality, and analgesia. These results differ considerably from our earlier meta-analysis that did not support the use of perineural dexmedetomidine. There is now strong evidence to support its effect in prolonging sensory block duration, and moderate evidence to supports its effect in hastening block onset and extending the duration of analgesia. However, these benefits should be weighed against the increased risks of motor block prolongation and transient bradycardia and hypotension.
